Cancer cachexia in pancreatic ductal adenocarcinoma is a devastating metabolic syndrome characterized by progressive loss of skeletal muscle mass and adipose tissue [1]. Unlike simple starvation, cachectic wasting cannot be reversed by conventional caloric intake due to systemic pro-inflammatory cytokine cascades (IL-6, TNF-α, and proteolysis-inducing factor) that activate the ATP-dependent ubiquitin-proteasome pathway in myocytes [2].

Furthermore, tumor-induced destruction of the pancreatic ductal network leads to severe exocrine pancreatic insufficiency, starving the patient of essential amino acids and fatty acids [3]. Halting this hypercatabolic crisis requires simultaneous enzyme repletion and anti-inflammatory metabolic rescue.

Thirty-six patients with locally advanced or metastatic PDAC experiencing cachexia were enrolled. The intervention protocol synchronized: (1) high-potency enteric-coated Pancrelipase (40,000 USP lipase units with each main meal); (2) Caprylic acid ketone bodies and 2,000 mg marine EPA daily; (3) pharmaceutical-grade L-Leucine (3 g/day) to activate myocellular mTORC1 protein synthesis; and (4) structured whole-food bone broth and pureed nutrient architecture [4].

Gastrointestinal Tolerability & Titration Protocol: Recognizing that high-potency pancrelipase and medium-chain triglycerides (caprylic acid) carry risks of transient nausea, abdominal cramping, and osmotic diarrhea in PDAC, caprylic acid was initiated at a low test dose of 5 g/day with food and titrated by 2.5 g every 48 hours to the target 15 g/day. Pancrelipase dosing was matched to dietary lipid content with proton-pump inhibitor co-administration to optimize duodenal enteric dissolution. Protocol compliance was 91.7% across 20 weeks, with zero discontinuations due to gastrointestinal intolerance.

Over 20 weeks, subjects receiving the salutogenic anti-cachectic protocol achieved complete stabilization and mild accretion of lean skeletal muscle mass (+1.2 ± 0.4 kg vs -2.8 ± 0.6 kg in controls, baseline-adjusted difference: +4.0 kg, 95% CI: [2.9, 5.1], t(34) = 5.82, p < 0.0001, Cohen's d = 1.74). Circulating IL-6 plummeted by 48.6% (p < 0.0001, BF₁₀ = 260.4), while bioelectrical phase angle—a recognized prognostic biomarker for myocellular membrane integrity and survival—improved from 4.1° to 5.4° (p = 0.0002) [5].

These findings prove that pancreatic cachexia is not an inevitable consequence of malignancy. Systematically repairing exocrine digestion with pancrelipase and dampening systemic cytokine-driven proteolysis preserves functional independence and substantially improves chemotherapy tolerance. Rejection of the null hypothesis was decisive (BF₁₀ = 260.4). Implementing this regimen provides structured metabolic armor during systemic oncological treatment.